# Phase II, Safety and Efficacy Study of Kamada-alpha-1-antitrypsin (AAT) for Inhalation"

> **NCT02001688** · PHASE2 · COMPLETED · sponsor: **Kamada, Ltd.** · enrollment: 36 (actual)

## Conditions studied

- Alpha-1 Antitrypsin Deficiency

## Interventions

- **DRUG:** Kamada-AAT for Inhalation, 80mg
- **DRUG:** Placebo
- **DRUG:** Kamada-AAT for Inhalation, 160mg

## Key facts

- **NCT ID:** NCT02001688
- **Lead sponsor:** Kamada, Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-04
- **Primary completion:** 2016-02
- **Final completion:** 2016-05
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2020-01-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02001688

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02001688, "Phase II, Safety and Efficacy Study of Kamada-alpha-1-antitrypsin (AAT) for Inhalation"". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02001688. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*